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SulTlmary 
Elevation of cAMP can cause gene-specific inhibition ofinterleukin 2 (IL-2) expression. To investigate 
the mechanism of this effect, we have combined electrophoretic mobility shift assays and in vivo 
genomic footprinting to assess both the availability of putative IL-2 transcription factors in forskolin- 
treated cells and the functional capacity of these factors to engage their sites in vivo. All observed 
effects of forskolin depended upon protein kinase A, for they were blocked by introduction  of 
a dominant  negative mutant  subunit  of protein  kinase A.  In the EL4.E1  cell line,  we report 
specific inhibitory effects of cAMP elevation both on NF-KB/Rel family factors binding at  -200 
bp, and on a novel, biochemically distinct "TGGGC" factor binding at  -225 bp with respect 
to the IL-2 transcriptional  start site.  Neither NF-AT nor AP-1 binding activities are detectably 
inhibited in gel mobility shift assays. Elevation of cAMP inhibits NF-KB activity with delayed 
kinetics in association with a delayed inhibition of IL-2 kNA accumulation. Activation of cells 
in the presence of forskolin prevents the maintenance of stable protein-DNA interactions in vivo, 
not only at the NF-KB and TGGGC sites of the IL-2 enhancer,  but also at the NF-AT, AP-1, 
and other sites. This result, and similar results in cyclosporin A-treated cells, imply that individual 
IL-2 transcription factors cannot stably bind their target sequences in vivo without coengagement 
of all other distinct factors at neighboring sites. It is proposed that nonhierarchical,  cooperative 
enhancement  of binding is a structural basis of combinatorial transcription  factor action at the 
ILo2 locus. 
A•ctivation 
of T  helper cells results in secretion of diverse 
lymphokines. The precise combination of lymphokines 
produced is variable,  depending on the circumstances of the 
activation process. Different effector mechanisms are triggered 
by different lymphokines. Locally and systemically, the rela- 
tive levels of different lymphokines with respect to one an- 
other strongly affect in vivo outcomes. Thus, the type of im- 
mune response that is mobilized ultimately depends on the 
differential transcriptional  regulation of lymphokine genes. 
The major stimulatory signal for lymphokine production is 
delivered by engagement  of the TCR with antigen  in the 
context of MHC on APCs. However, engagement of acces- 
sory molecules on the T  cell with additional ligands, either 
on APCs or in the microenvironment,  may also deliver other 
kinds  of  signals  that  affect  lymphokine  gene  expression 
differentially. Expression of the T  cell growth factor, IL-2, 
is particularly  susceptible to this kind of modulation. Glucocor- 
ticoids inhibit IL-2 induction preferentially (1-3), and con- 
tact of a T cell with antigen in the absence of a CD28 ligand 
can drive the T  cell into an anergic state in which IFN-y 
can be expressed, but not IL-2 (4, 5).  Agonists that elevate 
cAMP levels, such as prostaglandin E1 and E2, give especially 
clear evidence for selective inhibition of IL-2 expression (6, 
7), as they can inhibit  IL-2 expression in cases where there 
is no inhibition of IL-4 expression at all (8-10). The effects 
of cAMP on T  cells can be exerted at both cell- and gene- 
specific levels,  depending on the cells  and stimuli used.  In 
certain IL-2-producing cells, cAMP elevation can uncouple 
the TCR/CD3 complex from its downstream signaling medi- 
ators, preventing the generation of Ca  2§  and protein kinase 
C  signals (11-13).  On the other hand, even when Ca  z+ and 
protein kinase C signals are provided pharmacologically,  cAMP 
elevation can still interfere selectively with induction of IL-2 
gene expression, yet allowing other responses to proceed. It 
is the mechanism of this second, gene-specific effect that we 
investigate  here. 
The  IL-2  gene  regulatory  region  consists  of compact, 
clustered binding sites for an assortment of transcription factors 
that are disparately regulated (14). In most or all cases studied, 
IL-2 expression is induced only when all the known factors 
are present,  and the ILo2 promoter only works at maximal 
ef~ciency when all the major binding sites for these factors 
are intact.  However, in physiological situations,  data seem 
to indicate that certain factors play more critical roles than 
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to be rate limiting for IL-2 expression. When selective down- 
regulation of IL-2 production is caused by exposing T  cells 
to glucocorticoids, the possible mechanisms are a protein-pro- 
tein interaction that sequesters AP-1 by dimerization of AP-1 
components with the glucocorticoid receptor (2), or a specific 
inhibition of interaction between AP-1 and NF-AT (3). When 
IL-2-producing cells have been anergized and become un- 
able to express IL-2, their failure appears to be due to either 
a general block of NF-AT, NF-KB, and AP-1 activation (15), 
or  a  selective inability  to  activate  AP-1  (16).  The potent 
immune-suppressive drugs cyclosporin A (CsA) 1 and FK 506 
completely block IL-2 transcription by blocking the nuclear 
translocation of one component of NF-AT (17). Whereas this 
is an example of strictly pharmacological inhibition, defects 
in both  NF-AT  and  AP-I  mobilization  also  appear  to be 
responsible for a normal developmental block in the ability 
to express IL-2, namely in cortical thymocytes (18). A similar 
phenotype is observed in a pre-mast cell line that can express 
IL-4 but not IL-2 (19). Thus, an important question is whether 
all  physiological  regulation  of IL-2  expression  is  exerted 
through  effects  on  AP-1  or  NF-AT,  or  whether  cAMP- 
elevating agonists might inhibit IL-2 expression through effects 
on different factors. 
To address these questions,  we have chosen EL4.E1 thy- 
moma cells as  a model T  cell system,  and  the Ca 2+  iono- 
phore A23187 and the phorbol ester PMA (TPA) as stimulants 
that can bypass any effects of cAMP on signal generation at 
the cell membrane. Using this system previously, we showed 
that cAMP could inhibit IL-2 transcription (9). We also ob- 
tained initial indications that elevation of cAMP caused a slight 
decrease in the binding  activity of NF-xB, but did not in- 
hibit NF-AT or AP-1 site binding activities (20). In our present 
studies, we have clearly defined two specific effects of cAMP 
on factor-binding activities and examined the resulting pro- 
tein-DNA interactions at the IL-2 locus in vivo. Our results 
confirm that cAMP,  acting via activation of protein kinase 
A  (PKA),  selectively affects the in vitro DNA binding  ac- 
tivities of NF-KB and  a newly described TGGGC binding 
factor, and that it does so with novel and distinctively delayed 
kinetics.  No evidence was found for any negative effect on 
NF-AT or AP-1 binding.  However, cells stimulated in the 
presence of forskolin failed to sustain stable protein-DNA con- 
tacts  at  a broad array of sites spanning  the entire IL-2 en- 
hancer region.  The lack of occupancy may be evidence for 
a new role for NF-xB and TGGGC binding activities, as re- 
quired partners  in  transcription  complex assembly. 
Materials and Methods 
Cells.  EL4.E1 cells (EL4) were grown in RPMI-1640 in the 
presence of 2 mM L-glutamine,  50 mM 13-ME, antibiotics, and 6% 
1 Abbreviations used in  this paper: CsA, cyclosporin A;  DMS, dimethyl 
sulfate; EMSA, electrophoretic mobility shift assay; PKA, protein kinase 
A; TPA, 12-O-tetradecanoyl  phorbol 13-acetate (PMA). 
fetal bovine serum (Hyclone, Logan, UT). Cells were cultured to 
confluence before stimulation and were stimulated at 1-2  x  106 
cells/ml using 17 nM TPA and 120 nM A23187 in the presence 
or absence of 10/~M of forskolin (Sigma Chemical Co., St. Louis, 
MO), which raises the cAMP level by directly activating adenylate 
cyclase. Recombinant human IL-la (Genzyme Corp., Cambridge, 
MA) was used at 50 U/ml. 
11,2 Analysis.  RNase probe protection analysis to quantitate 
IL-2 RNA was performed as previously described (19, 21). For each 
sample, 10/xg of RNA was used to hybridize with the 11,-2 probe 
(22), and 1/~g RNA was used to hybridize with either an actin 
or glyceraldehyde-3-phosphate dehydrogenase (GAPDH) probe (23). 
Cyclic AMPAssay.  Levels  of cAMP were measured in EL4 cells 
as described previously using an Amersham dual-range cAMP kit 
(9), except that nonacetylated standards  and samples were used. 
Gel Mobility shift Assays.  Nuclear extracts of EL4 cells were 
prepared as before (18). Double-stranded oligonucleotide corre- 
sponding to portions of the mouse IL-2 gene regulatory region were 
labeled by end filling with c~-[32p]deoxynucleoside triphosphates. 
The detailed sequences and corresponding sites relative to the tran- 
scription start site were described elsewhere (18-20).  Oligonucleo- 
tides used for this experiment were synthesized in the California 
Institute of Technology Biology Microchemical Facility. The binding 
reaction and gel electrophoresis procedures were exactly as reported 
before (18). Note that these conditions for detection of NF-AT site 
binding activity differ from those we used in initial studies  (20), 
as poly (dI-dC) is used as a nonspecific competitor in place of poly 
(dA-dT). In our hands,  this substitution yields a spectrum of gel- 
shift complexes more consistent with NF-AT complexes described 
elsewhere,  and less dominated by highly protease-sensitive  com- 
plexes. However, the insensitivity of NF-AT site binding factors 
to forskolin reported in our earlier study (20) is confirmed here. 
In vivo Footprinting  Analysis.  The genomic footprinting anal- 
ysis was done as before with the same set of IL-2 gene primers pre- 
viously reported (19). Briefly, 3  x  107 cells were concentrated into 
1 ml medium, and treated with 0.1% of dimethylsulfate at 37~ 
for 1 rain. The reaction was stopped by transferring the cells to 
a tube containing 49 ml of ice-cold PBS, and the cells were pelleted 
and washed once more with 50 ml PBS. The cell pellet was then 
resuspended in 3 ml of lysis buffer (300 mM NaC1, 50 mM Tris, 
pH 8.0, 25 mM EDTA, pH 8.0, 200/xg/ml proteinase K, and 0.2% 
SDS), and incubated at 37~  overnight. Nucleic acids were obtained 
by phenol/chloroform extraction and isopropanol precipitation, then 
subjected to piperidine cleavage and subsequent ligation-mediated 
PCR (24).  The final labeled  PCR products were separated  on a 
6% polyacrylamide sequencing gel. 
Transfection and Selection.  10 #g of linearized HL-REV~pKOneo 
(designated  pAPKA in the text) (a gift from G.  S.  McKnight, 
University of Washington, Seattle, WA) was electroporated at 960 
#F and 320 V into 107 EL4.E1 cells in 1 ml of serum-free RPMI- 
1640 medium with supplements and 14.4 mM H-ME.  The cells 
were then diluted into 50 ml of medium and plated in two 24-well 
plates (1 ml/well). 2 d after plating, G418 (GIBCO BRL, Gaithers- 
burg, MD) was added to the wells at 400 #g/ml.  Positive wells 
were identified 7-10 d after selection and the cells were expanded 
in 200/xg/ml G418 for further analysis. The plasmid DNAs, pBR322 
and pSV2neo (25), were used in transfection as negative and posi- 
tive controls. Integration of the mutant PKA construct in estab- 
lished transfectant lines was confirmed by Southern blot analysis 
and its expression was further confirmed by Northern blot anal- 
ysis. One mutant PKA transfectant line, IIA4, and two pSV2neo 
control lines were used in the subsequent experiments. 
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Forsteolin  Affects  DNA-binding  Activities  of a Specific  Subset 
of Factors.  To investigate the effects of cAMP on IL-2 tran- 
scriptional  control,  EL4 cells were  stimulated  with  TPA+ 
A23187  in  the presence or  absence of 10/zM  of forskolin, 
and the IL-2 mRNA  level in the cells was examined 5 h after 
induction  (Fig.  1  A).  Addition  of  forskolin  to  the 
TPA+A23187 stimuli significantly decreased the level of IL-2 
mRNA  (Fig.  1 A, lane 3). In previous work (9), we reported 
that  forskolin  could  also  inhibit  inducible  expression  of a 
reporter gene under the control of the minimal 321-bp IL-2 
promoter/enhancer.  This indicated  that  at least part  of the 
effect of forskolin  was  mediated  through  the  5' regulatory 
sequence of the IL-2 gene,  presumably at the level of tran- 
scriptional  initiation,  and  that  the  "~300 bp  minimal  pro- 
moter/enhancer  sequence was sufficient  to produce  this  re- 
sponse. Therefore, to determine the mechanism of the forskolin 
inhibition  effect, we focused on protein-DNA  interactions 
in  this  300-bp  region. 
To ascertain whether forskolin inhibits the binding of par- 
ticular  factors to  the IL-2 regulatory region,  we compared 
the levels of most DNA binding activities known to be cor- 
related  with  IL-2  gene  activation  in  nuclear  extracts  from 
stimulated cells and from cells stimulated in the presence of 
forskolin.  Nuclear extracts were prepared from EL4 cells in- 
cubated under different conditions  for 4-5  h,  and these ex- 
tracts were analyzed for sequence-specific binding  activities 
by electrophoretic  mobility shift assays (EMSAs)  (Fig.  1, B 
and C). Double stranded oligonucleotide probes were chosen 
to  span all  the major  sites  of protein-DNA  contact  in  IL- 
2-producing EL4 cells,  as previously identified by in vivo foot- 
printing  (19).  As shown in Fig.  1 C,  the DNA  binding ac- 
tivities of factors that are constitutively present,  such as the 
Figure  1.  II.-2  expression and nuclear DNA-binding activities in EL4 
cells after stimulation in the presence or absence of forskolin. (A) RNase 
protection analysis of IL-2 RNA expression. Total cytoplasmic RNA (10 
#g) from unstimulated cells (lane 1), from cells stimulated for 5 h (lane 
2) with TPA+A23187, or from cells stimulated for 5 h with TPA+A23187 
in the presence of forskolin (lane 3), or 30 #g of yeast tRNA (lane 4) 
were hybridized with IL-2 probe or a control GAPDH probe and quanti- 
tated by ribonuclease  protection assay.  (B) EMSAs of NF-KB and TGGGC 
DNAobinding activities. Corresponding nuclear extracts from the same 
populations of EL4 cells used in A were tested for NF-KB (lanes I-3) and 
TGGGC (lanes 4-6) site binding activities. (C) EMSAs of other factors. 
Nuclear extracts corresponding to the same three populations (unstimu- 
lated, lanes 1, 4, 7, I0, 13, and 16; stimulated, lanes 2, 5, 8, 1I, 14, and 
17; and stimulated for 5 h in the presence of forskolin for 5 h, lanes 3, 
6, 9,  12,  15, and 17) were compared for binding activities to the distal 
NF-ATd site (lanes I-3), the proximal NF-ATp  site (lanes 4-6), the AP-1 
site (7-9), the distal CACCCd site (lanes I0-12), the proximal CACCCp 
site (lanes 13-15),  and proximal octamer (16-18) sites. Large arrowheads 
in B and C indicate the major complexes at each site. At the Oct site, 
the complexes are likely to represent Oct-l, Oct-2B, and Oct-2A. Minor 
complexes at the CACCC site (small arrowheads) are discussed in the text. 
(-) Unstimulated; (+) stimulated; and (F) stimulated in the presence of 
forskolin. 
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proximal octamer site, were not affected by forskolin (Fig. 
1 C, lanes 10-18, large arrowheads). Similarly, some induction- 
dependent activities, such as the major inducible complexes 
binding the NF-AT and AP-1 sites, were unaffected or even 
slightly enhanced by stimulation in the presence of forskolin 
(Fig.  1 C, lanes  1-9,  large arrowheads).  These results are in 
agreement with our previous conclusions from more limited 
studies (20). However, as shown in Fig. 1 B, binding activi- 
ties of several other inducible factors were significantly re- 
duced in nuclear extracts from cells  that were activated in 
the presence of forskolin. Most prominent among these were 
the upper complexes binding to the NF-KB and TGGGC sites 
(Fig.  1 B, lanes 2, 3 and 5, 6). In addition, we noted effects 
of forskolin on minor complexes binding the two CACCC 
sites, which in both cases were of faster mobility than the 
major CACCC complex (Fig.  1 C, lanes 11, i2, and 14,  15, 
small arrowheads).  The identities of the lower inducible com- 
plexes bound to the CACCC sites are not known. They could 
not be competed by a consensus Sp-1 oligonucleotide as could 
the  major  CACCC  binding  complexes (18,  and data  not 
shown).  The nature of the TGGGC binding factor is also 
not known. As it appeared to show a similar electrophoretic 
mobility to that of the upper NF-KB complex, it was sub- 
jected to some further characterization. 
Although both NF-KB and TGGGC binding activities were 
coinhibited by forskolin, the protein components involved 
were clearly different. This was confirmed by the demon- 
stration, (a), that the TGGGC and NF-KB binding sites could 
not cross-compete in mobility shift assays, and (b), by anti- 
body supershift experiments in which anti-p65,  anti-c-tel, 
and anti-p50 antibodies that could supershift or inhibit the 
NF-KB complexes were all completely unable to affect  the 
TGGGC complexes (data not shown). Furthermore, whereas 
TNF-ol could "rescue" NF-KB binding activity in cells stimu- 
lated in the presence of forskolin, there was no rescue of the 
TGGGC factor (data not  shown).  These results,  and data 
presented below, show that the regulation of activation of 
these two binding activities was different. 
The presence of forskolin during stimulation appeared to 
result in a reduction in the total amount of NF-KB complexes 
per cell, not simply a sequestration of NF-KB activity (26). 
This was  shown both by Western blotting of nuclear and 
cytoplasmic extracts with antibodies against p65, p50, and 
c-rel, and by using deoxycholate to dissociate NF-KB/IKB com- 
plexes, thus revealing previously masked NF-KB binding ac- 
tivities (27).  Stimulation for 4 h led to a sharp increase  of 
p65/p50 and c-rel/p50 complexes in the nucleus,  and this 
increase was profoundly antagonized by the presence of for- 
skolin. However, there was no compensatory  increase in NF-KB 
components or binding activities in the cytoplasm (data not 
shown). Thus, forskolin may inhibit NF-gB synthesis or pro- 
mote NF-KB degradation. 
Delayed Inhibition  of lL-2 Expression  Via Delayed Inhibition 
of NF-KR  The effects of forskolin on NF-KB appear to be 
paradoxical, for it has been reported that PKA can activate 
NF-gB, and our own earlier study (20) did not show consis- 
tent reduction of NF-KB binding at 2 h of forskolin treat- 
ment.  To clarify this contradiction, we did kinetic studies 
to see whether the reduction we observed here is an early 
event or a possible secondary effect. First, we examined the 
kinetics  of cAMP  elevation  after  forskolin  treatment.  A 
significant increase in cAMP levels could be seen 15 minutes 
after administration of forskolin, reaching a maximum within 
an  hour.  High levels of cAMP were then retained for up 
to 6 h  of forskolin treatment (Fig.  2 A).  The addition of 
TPA+A23187 did not affect the initial elevation or the later 
accumulation of cAMP (Fig.  2 B). Pretreatment of cells for 
2 h with TPA+A23187 before addition of forskolin also did 
not significantly affect the subsequent elevation of cAMP (Fig. 
2 C). The high levels of  cAMP sustained for many hours made 
it possible that  cAMP-dependent mechanisms  could exert 
effects at late time points, not just immediately after stimu- 
lation. 
In fact, the effects of forskolin on NF-KB and TGGGC 
binding factor induction showed strikingly different time 
courses.  When cells were activated in the presence of for- 
skolin, mobilization of the factors binding to the TGGGC 
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Figure 2.  Sustained  elevation  of  cAMP  as a func- 
tion of  duration of  forskolin  treatment. The figure 
shows cAMP  levels  in EL4 cells that were  cultured 
in the presence  of forskolin  alone (solid and dotted 
curve, A; solid  curve,  B and C); with TPA+A23187+ 
forskolin added simultaneously  (dots, B); or with 
forskolin added (time 0) after  2 h of pretreatment 
with TPA+A23187 (dots, C). Levels  of cAMP are 
also shown for IIA4 transfectants (see Fig. 4) that 
were cultured with forskolin  alone (triangles, A). 
The incubation  was stopped  at different  time  points 
and cAMP was measured  in aliquots of 10  s cells. 
As a reference  for the data in A-C, the data from 
EL4 cells  treated  with forskolin  alone  (A) were  used 
to calculate the solid curve shown in all three panels. Individual data points were plotted as triangles or dots to compare  with the solid curve. This 
comparison emphasizes the similarity  in the kinetics of cAMP accumulations  with or without stimulation. The experimental  data for forskolin-treated 
EL4 cells (solid cuwe) are well-represented  by the equation C(,  ) = Ks/Kd  -  (Ks/Ka -  C0)exp(-Kat),  where C(0 is the amount (fmol) of cAMP/106 
cells at time t (h). Co (=568 fmol/106 cells) is the amount of cAMP at time 0, Ks (=1.6 x  104 fmol/106 cells h) is the calculated cAMP synthesis 
rate constant in the presence of forskolin. Ka (=1.14 h -1) is the cAMP decay rate constant, from which we compute tl/2 = 0.79 h. 
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correlated with delayed  inhibition of  NF-KB  binding activity. 
(A) NF-KB  and TGGGC site binding activities  were measured 
at different intervals of stimulation  (~),  in the presence 
(F-I), or absence of forskolin, as indicated in the bar graph 
over each lane. Note that it took 4 h of forskolin treatment 
to reduce NF-KB binding activity, whether  forskolin addi- 
tion was delayed  or not (lanes 6 and 7), but only 2 h to reduce 
TGGGC binding activity significantly (lanes 10 and 11). (B) 
IL-2 mRNA levels  at various times of stimulation were mea- 
sured by RNase protection analysis. Data were collected from 
two independent experiments. (Left) Cells stimulated for the 
indicated lengths of time in the absence  ([/]) or presence (￿9 
of forskolin from time 0. (Right) Forskolin and CsA chase 
experiments. All samples  were stimulated from time 0. For- 
skolin (O) or CsA (D) was added to the culture 2 h after 
initiating  the stimulation with TPA+A23187. 
site was inhibited  both  at  2  and  at  4  h  of treatment  (Fig. 
3  A,  compare lanes 9  and  11,  12,  and  14),  indicating  that 
this  inhibition  is  an early event.  However,  when  analyzed 
after 2 h  of stimulation,  NF-KB binding  activities appeared 
to be induced equally well whether forskolin was present or 
not  (Fig.  3  A,  compare lanes  2  and  4).  Only  after at least 
4  h  of stimulation  in  the  presence  of forskolin  did we  see 
the characteristic decrease of the NF-KB site binding activity 
(Fig.  3 A, compare lanes 5 and 7). These findings indicated 
that elevation of cAMP does not inhibit  the initial dissocia- 
tion of NF-rB  from IKB or its subsequent  nuclear localiza- 
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tion.  They also suggested either that the effects of forskolin 
on NF-KB were intrinsically subject to delay, or that NF-KB 
proteins only became susceptible to forskolin-dependent  in- 
hibition  at  some point  at least  2  h  after initial  exposure to 
TPA+A23187.  To test these possibilities, we first stimulated 
the cells with TPA and A23187 for 2 h, to make all the neces- 
sary trans-acting factors available and initiate transcription of 
IL-2 RNA,  then we introduced  10/zM forskolin to the cul- 
ture and continued the culture for another 2 or 4 h. As shown 
in Fig.  3 A  (lanes 3  and 6),  forskolin "chasing" for 2 h  still 
had little effect on NF-KB binding, but chasing for 4 h greatly reduced the binding. These results suggested that PKA acti- 
vation had an intrinsically delayed effect on NF-KB binding 
activity. 
The delayed and asynchronous effects of cAMP elevation 
on the NF-KB and TGGGC site binding factors were associated 
with delayed inhibition of IL-2 mRNA expression,  as shown 
in Fig. 3 B. IL-2 mR.NA accumulation in the stimulated con- 
trol cells followed biphasic kinetics with a relatively low rate 
of accumulation in the first 2 h, which then shifted to a higher 
rate that was sustained for the next 4 h. When forskolin was 
present at the start of stimulation, IL-2 mRNA initially ac- 
cumulated almost as fast as in the control cells without for- 
skolin, but then declined to baseline  between 2 and 4 h of 
stimulation (Fig. 3 B, left). When the addition of forskolin 
was delayed until after 2 h of stimulation, the rate of IL-2 
mRNA accumulation was significantly  reduced as compared 
with the control samples without forskolin, and inhibitory 
effects were evident within the first 2 h of forskolin chasing 
(Fig. 3 B, right). However, this inhibition was slow as com- 
pared with the immediate shut-off of IL-2 mRNA accumu- 
lation when CsA, instead of forskolin, was added after 2 h 
of stimulation (Fig. 3 B, right). Thus, some early effects of 
forskolin which inhibit IL-2 activation may be exerted be- 
fore its effects on NF-~cB, suggesting that a lack of factors 
other than NF-KB, including the TGGGC binding factor, 
may be sufficient to hinder the transcription but not to block 
it fully. The reduced NF-KB binding activity seen at rela- 
tively later time points would then be associated  with the 
complete arrest of IL-2 mR.NA accumulation. 
Effects of Forskolin Are Mediated by PKA.  Forskolin ele- 
vates intracellular cAMP by directly activating adenylate ey- 
clase, and cAMP in turn activates cAMP-dependent protein 
kinases (PKA). To ascertain  whether all the effects of for- 
skolin depend on the activation of PKA, we introduced a 
dominant negative mutant PKA regulatory subunit cDNA 
construct, driven by the Harvey sarcoma virus LTR, into EL4 
cells (28).  The product encoded by this construct has two 
point mutations at cAMP-binding sites which block its binding 
to cAMP but  still allow it  to associate  with the catalytic 
subunits in competition with endogenous regulatory subunits. 
Once bound,  the mutant regulatory subunit will not dis- 
sociate from the catalytic subunit in response  to cAMP and 
therefore acts as a dominant negative regulator of PKA ac- 
tivity. One stable transfectant line showing high expression 
of the mutant subunit, IIA4, and two pSV2neo transfectant 
control lines, were tested to compare their forskolin responses. 
As shown in Fig. 2 A  (triangles), the introduction of the mu- 
tant subunit had no effect on the ability of the cells to elevate 
their cAMP levels in response to forskolin. However, the mu- 
tant  subunit  completely protected  the  induction of IL-2 
mRNA from forskolin inhibition in the IIA4 line, in con- 
trast to the significant inhibition of IL-2 expression  by for- 
skolin in control lines as measured 4 h after stimulation (Fig. 
4 A). In agreement with its effects on IL-2 mRNA expres- 
sion, expression of the dominant negative mutant PKA also 
relieved  the inhibitory effects of forskolin on  NF-KB  and 
TGGGC binding activity (Fig. 4 B). The NF-KB and TGGGC 
Figure  4.  Dominant  negative  mutant PKA transfected  cells are resis- 
tant to the forskolin  inhibitory  effect. (A) Levels  of II.-2 mRNA induced 
in two control lines of pSV2neo transfectants,  IB2 and IB6, and in one 
line of  mutant  PKA transfectants,  IIA4, were  compared  by RNase protec- 
tion analysis  with 10 #g of RNA from  uninduced  cells (-), or cells after 
4-h stimulations  (+) in the absence or presence (F) of forskolin. 1 #g of 
RNA from each sample was hybridized  with actin probe to verify  com- 
parability  and integrity  of the R.NA. (B) Nuclear  extracts from  IIA4 cells 
were tested  for NF-KB and TGGGC  binding activities. All stimulations 
were for 4 h. (-) Uninduced; (+) induced  with TPA and A23187; (F) 
induced with TPA and A23187 in the presence of forskolin; (/) induced 
with TPA and A23187 in the presence of 50 U/ml IL-1. 
binding complexes,  and the two lower inducible CACCC 
binding complexes, were fully inducible in the mutant PKA- 
containing cell line IIA4 whether forskolin was added or not 
(compare Figs. 4 B and 1 B; and data not shown). The binding 
activities  of other factors in forskolin-treated IIA4 cells re- 
mained the same as in cells stimulated without forskolin (data 
not shown). The mutant cells were not simply refractory to 
modulation of NF-t~B activity, for they remained capable of 
upregulating their NF-KB site binding activity upon stimu- 
lation in the presence  of 50  U/ml  IL-1 (Fig.  4 B,  lane 4) 
(20). Therefore, it is clear that PKA is a mediator of the in- 
hibitory effects of forskolin on DNA-binding activities. 
Forskolin Inhibits Stable In Vivo  Assembly of  the IL-2 DNA- 
Protein Complex.  The highly selective effects of forskolin on 
particular  DNA-binding  activities  raised  the  question  of 
whether the binding activities that remain are  capable  of 
forming stable contacts with IL-2 regulatory DNA in the 
nuclei of forskolin-treated, stimulated cells. To resolve this 
issue, living cells were treated with dimethyl sulfate (DMS), 
which methylates G residues  (met-G) in the major groove. 
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tect them from methylation or make them hypersensitive to 
methylation.  The subsequent piperidine cleavage of the ex- 
tracted DNA at met-Gs followed by ligation-mediated PCR 
amplification generates a G-specific sequence ladder. In fact, 
this technique has revealed specific major groove contacts at 
most or all of the sites known to be required for IL-2 expres- 
sion (19). In agreement with the results we have shown pre- 
viously (19),  there is no obvious difference in the G ladder 
pattern between the DNA from DMS-treated, uninduced cells 
and  naked  control  DNA  which  was  DMS  treated  after 
purification (Fig. 5 A, lanes 1, 2, and 5). However, multiple 
footprints  spanning  almost the entire 300-bp upstream  se- 
quence were found in DNA from cells  stimulated for 4 h 
with TPA+A23187 in the absence of forskolin, which cor- 
responded to the well-characterized c/s elements noted previ- 
ously (Fig.  5, compare lanes 2 and 3 in A  and lanes 1 and 
2 in B). Whereas these DMS footprinting results do not rule 
out some form of protein-DNA associations  at the IL-2 locus 
in uninduced cells,  such associations clearly do not include 
the diagnostic,  specific  contacts that  are formed at regula- 
tory sites in induced cells. As noted above, these specific sites 
of occupancy define the oligonucleotide probes used in Fig. 
1. Each site was revealed in vivo by protection (O~),  hyper- 
sensitivity ( ~  ),  or a characteristic  pattern  of both;  ex- 
amples are shown in Fig. 5 C. As previously discussed (19), 
G  residues in the footprint  are never completely protected 
from cleavage, and this effect is exacerbated by the asynchrony 
of IL-2 transcription in the stimulated population, in contrast 
with the more complete protection  seen in the regulatory 
sequence of a constitutively expressed gene such as metal- 
lothionein-I (19, and data not shown). However, the pattern 
of protections and hypersensitivities  at the IL-2 locus in stimu- 
lated cells  was still highly reproducible. 
When examining the DNA from cells induced for 4 h in 
the presence of forskolin,  pronounced differences from the 
characteristic induced pattern  were noted.  First,  at  almost 
every cis element,  signs of occupancy were absent  (Fig.  5, 
A,  lane 4  and B,  lane 3).  Not only were the NF-KB and 
TGGGC sites empty, but the two NF-AT sites  (Fig.  5 C), 
the AP-1 site and the proximal CACCC site also remained 
unoccupied, even though the factors binding these latter sites 
were present in the nucleus and were able to bind to their 
sites individually as shown by in vitro mobility shift studies 
(see above, Fig.  1). The global blockade of stable footprint 
formation  is reminiscent  of the CsA effect, which tightly 
shuts off IL-2 transcription and completely eliminates all evi- 
dence for protein-DNA interaction in footprinting analysis 
(19 and see below). Only one sign of protein-DNA interac- 
tion was consistently seen in the cells stimulated in the pres- 
ence of forskolin: a persistent hypersensitivity at the 5'-most 
G  in  the distal CACCC element.  The  significance of this 
isolated feature, at the border of the known IL-2 enhancer, 
is unknown. 
The elimination of protein-DNA contacts in cells that had 
been stimulated in the presence of forskolin was dependent 
on PKA activity, as shown with DNA samples from mutant 
PKA transfectants.  Like the parental cells,  IIA4 cells estab- 
lished a full range of protein-DNA contacts in response to 
TPA+A23187 (Fig.  5, A, lane 6; B, lane 5). In contrast to 
the wild-type parental EL4 cells, treatment of IIA4 cells with 
forskolin did not affect any of the TPA+A23187-induced pro- 
tections and hypersensitivities on the DNA sequence ladder 
(Fig.  5,  compare lanes 4 and  7 in A  and lanes 3  and 6 in 
B). Thus the disruption of protein-DNA contacts at the IL-2 
locus was a specific  effect of PKA activation. 
The effect of cAMP elevation on protein-DNA  contacts 
differed from that of CsA, described previously (19), in that 
the initial establishment of footprints proceeded normally in 
the presence of TPA+A23187 + forskolin, for example as mea- 
sured after 2 h of stimulation (data not shown). The absence 
of footprints at the later time points thus reflected the net 
disassembly of preexisting complexes. To confirm the ability 
of forskolin treatment  to block continuation  of occupancy, 
we examined DNA samples from two independent forskolin 
chasing experiments (Fig. 6). In agreement with the binding 
studies and RNA analysis,  the results  showed that  2 h  of 
forskolin chasing after 2 h of stimulation did not change the 
preexisting footprints formed after 2-h stimulation  (Fig.  6, 
lane 3). By contrast, the same 2-h chase with CsA completely 
reversed the stimulated footprint pattern to an "uninduced" 
one (Fig.  6, lane 4). When forskolin chasing was extended 
to 4 h, however, a gradual weakening of protein-DNA  in- 
teractions  was  seen  (Fig.  6,  lane  9).  Notably,  footprints 
weakened at all sites concomitantly, with the unstimulated 
pattern reemerging  as quickly at the NF-AT  site as at the 
NF-KB site. Thus, even preformed IL-2 DNA-protein com- 
plexes are not  stable in vivo in activated cells without  the 
continued  contribution  of forskolin-sensitive components. 
Discussion 
Agonists that elevate intracellular cAMP are likely modu- 
lators of immune responses in vivo (6-10).  We and others 
have previously shown that they selectively interfere with IL-2 
expression.  Here we also report that the inhibition can follow 
a distinctively delayed time course, allowing an initial limited 
burst of IL-2 expression before transcription  ceases.  These 
qualitative  and kinetic  effects on cytokine gene expression 
resulting from the elevation of cAMP could be used in vivo 
to play a role in the shaping  of a Th2 vs.  Thl  response. 
In this work, we present molecular evidence for the way 
elevation of cAMP downregulates expression of the IL-2 gene 
in a model cell line. At least two transcription  factors associated 
with  IL-2 activation,  including  NF-KB and the newly de- 
scribed TGGGC-binding factor, were specifically reduced in 
nuclear extracts from cells that were activated in the presence 
of forskolin. This pattern of transcription  factor inhibition 
differed markedly from the patterns of inhibition by CsA treat- 
ment or anergy induction, in that neither NF-AT nor AP-1 
binding activities were detectably reduced. With a closer look 
at protein-DNA interactions by in vivo footprinting, we dis- 
covered that the loss of the NF-KB and TGGGC binding ac- 
tivities was correlated with the disappearance of stable pro- 
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enhancer. Thus, cAMP-sensitive transcription factors appear 
to be as necessary as the CsA-sensitive factors described pre- 
viously (19) for the maintenance of transcription factor com- 
plexes at  the  IL-2 locus. 
Mechanism  of Forskolin Effects on NF-rB.  All the inhibi- 
tory effects of forskolin treatment studied here were executed 
by cAMP-dependent  protein  kinases,  since cells  expressing 
a dominant negative PKA mutant were completely resistant 
to forskolin effects. These cells preserved a high level of IL-2 
mRNA accumulation, full NF-KB and TGGGC binding ac- 
tivities in their nuclear extracts, and persistent high affinity 
protein-DNA interactions at the IL-2 locus even in the pres- 
ence of forskolin.  In some cellular contexts,  NF-KB can be 
activated by PKA (26, 29-31),  but in stimulated EL4 cells, 
the net role of PKA is to inhibit NF-KB availability.  Because 
it was not a complete failure of NF-rB induction but rather 
an inability to sustain NF-KB activation that  was observed, 
it remains possible that early PKA activation might initially 
synergize with PKC to activate NF-KB through  immediate 
IrB phosphorylation (27, 29-31). However, recent work has 
described additional pathways for PKA that provide a basis 
for delayed effects.  It was reported that  it takes 30 min for 
the catalytic subunit of PKA to translocate  to the nucleus, 
and phosphorylation of the cAMP response factor CREB and 
CREB-dependent gene activation occur only afterwards (32). 
Thus a delayed effect of cAMP elevation on NF-rB levels would 
be expected if the inhibition were dependent on de novo tran- 
scription of some target gene.  Preliminary experiments did 
not reveal  qualitative differences between the types of NF- 
rB/c-Rel complexes induced  at  2  h,  at  4  h,  and at  2  h  in 
the presence of forskolin  (data  not  shown).  However, any 
sustained NF-rB activation,  as observed in stimulated EL4 
cells, requires both new synthesis and ongoing nuclear trans- 
location of NF-rB molecules (33).  Forskolin could interfere 
with this by (a) causing direct cAMP-dependent repression 
of ongoing NF-rB subunit transcription;  (b) causing cAMP- 
dependent overexpression of an appropriate form of IrB; or 
(c) directly or indirectly stimulating NF-KB proteolysis. The 
degree to which each of these mechanisms contributes to the 
lagged inhibition  of NF-rB binding  activity remains  to be 
determined. 
How Are Reduced  NF-rB and TGGGC Binding Activities 
Related  to  the  Inhibition  of IL-2  Gene  Expression?  In  our 
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DNA  binding  complexes at  multiple sites of the 
IL-2 promoter/enhancer  region. In vivo  genomic foot- 
printing on IL-2 300-bp promoter/enhancer regions 
was performed with DNA samples from EL4 (lanes 
2-4, A  and lanes I-3, B) and IIA4 cells (lanes 5-7, 
A and lanes 4-6, B) cultured under different condi- 
tions. Resulting  ladders  for the coding  strand  are shown 
in A, and for the noncoding strand in B. (C) A close 
view of the effects  of forskolin  treatment on footprints 
at the distal and proximal NF-AT sites. (A and B) 
Specific  sites and the distance  relative  to the transcrip- 
tion start site are as indicated. (N) Naked  DNA sample 
from EL4 cells; ( - ) unstimulated cells; (+) induced 
with  TPA+A23187 for  4  h;  (F)  induced with 
TPA+A23187  + forskolin  for 4 h. Comparing lanes  be- 
tween the uninduced and induced samples, multiple 
footprints throughout  the whole 300-bp region are 
dearly observed,  consisting  of  reproducible  partial pro- 
tections (O1~) and hypersensitivities  (  .-~ ). In the 
forskolin-treated  EL4  lane, the sequence  hdder gener- 
ally resembles  the uninduced one, with the exception 
of the hypersensitive  G in the distal CACCC site (non- 
sense strand), as noted in the text. However, as seen 
in lanes 5-7 for both strands, forskolin did not affect 
the footprint formation in IIA4 cells. This subline ex- 
hibited relatively  weak footprints in general,  but there 
was no significant difference  between the footprints 
in induced samples of the mutant cells whether for- 
skolin was present or not. 
previous studies (19), we described three extreme situations: 
when the IL-2 gene was silent, fully activated, or suppressed 
by CsA.  Each condition was associated with the availability 
of a different spectrum of IL-2 DNA binding proteins as as- 
sayed in nuclear extracts. However, in vivo footprints revealed 
a  simpler  dichotomy,  with  either  no  detectable occupancy 
or a fully occupied footprinting pattern (Fig.  7). This indi- 
cated  that  in  vivo,  transcription  factors  interact  with  IL-2 
regulatory DNA in a highly coordinated, all-or-none fashion. 
The effects of forskolin treatment  on in vivo footprints  at 
the IL-2 locus enhance the previous conclusion in three ways. 
First, the key finding is that exposure to forskolin during 
stimulation blocks the formation of stable footprints at vir- 
tually all the sites of protein-DNA  contact  that  we detect 
in the IL-2 enhancer. In nuclear extracts from forskolin-treated 
cells,  almost  all the major binding  activities for these sites 
appeared to be available at normal levels; only two major corn- 
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plexes,  the  upper  NF-~B  and  TGGGC  complexes,  were 
affected. Yet in the nuclei of living,  forskolin-treated cells, 
none of the binding activities could in fact engage their target 
sites in the context of the full IL-2 enhancer (Fig. 7). In vivo, 
the binding of forskolin-insensitive factors like NF-AT was 
therefore contingent upon the binding of forskolin-sensitive 
factors like NF-~B.  This finding parallels the effect of CsA 
on the establishment of stable contacts (19, and Fig. 6). How- 
ever, as summarized  in  Fig.  7,  a different subset  of factors 
is prominently affected by each inhibitor.  The effect of CsA 
treatment, considered alone, made it possible to speculate that 
a single CsA-sensitive factor, like NF-AT, might play a unique 
role in opening the IL-2 chromatin  structure for transcrip- 
tion.  However, considered in light  of the similar effects of 
forskolin treatment, such a model is much less likely. A prob- 
able inference from the results summarized in Fig.  7 is that 
the assembly of stable transcription factor complexes at the Figure 6.  Forskolin has delayed effects on the stability of preformed 
protein-DNA  complexes. In vivo footprints at three regions of the IL-2 
regulatory sequence (sense strand) are shown. The data in lanes 1-4 and 
in lanes 5-9 are from two independent experiments.  Lanes 1 and 5 contain 
DNA from uninduced cells. Lanes 2 and 6 contain DNA from cells in- 
duced with TPA+A23187 for 2 h. In lanes 3 and 4, cells were stimulated 
for 2 h, and then forskolin (lane  3) or CsA (lane  4) were added for another 
2 h. In lane 3, the inducible footprints seen in lane 2 remain identifiable. 
However, in lane 4, those inducible footprints seen in lanes 2 and 3 disap- 
pear and the overall sequence  ladder approaches  the uninduced state seen 
in lane 1. In lane 7, cells were stimulated for 4 h without inhibitor. In 
lane 8, cells were stimulated for 4 h with forskolin added from time 0. 
In lane 9, cells  were prestimulated for 2 h, then incubated with forskolin 
for another 4 h. Stimulated samples without inhibitors (lanes 2, 6, and 
7) are indicated with asterisks. 
IL-2 locus requires muhivalent protein-protein interactions 
as well as  the protein-DNA  interactions  at  the individual 
sites. Thus, a major component of the combinatorial action 
of these transcription factors may be the cooperativity required 
for their  binding. 
Second, a further clue to support the need for cooperative 
binding  in IL-2 regulation may be provided by the persis- 
tence  of  a  sole  residual  site  of  activation-associated  pro- 
tein-DNA  contact in nuclei of forskolin-treated cells, long 
after other footprints have disappeared. The transcription factor 
or nucleosomal  structure responsible for this feature is un- 
known.  The  isolated  DMS  hypersensitivity  at  the  distal 
CACCC site is a structure that is not only distinguished from 
the resting state and the fully activated state of the IL-2 locus, 
but also distinguished from the state of the IL-2 locus in cells 
activated in the presence of CsA. The equivalence of the CsA- 
treated pattern with the resting (uninduced) pattern had not 
allowed us to distinguish whether limited chromatin accessi- 
bility or a requirement for cooperative binding  actually re- 
stricted  occupancy.  However, it  is less likely that  "accessi- 
bility" is limiting after PKA activation, since residual CACCC 
occupancy is  still  permitted  in  forskolin-treated cells. 
Finally, the effect of forskolin differs from that of CsA (19) 
in that the presence of forskolin does not block transcription 
factor binding initially.  In fact, the time course of its effect 
on in vivo protein-DNA contacts is delayed in parallel with 
the effect on NF-KB availability. This indicates that a key role 
is played by NF-KB or by a factor(s) inhibited with a similar 
time course. The transient assembly and disassembly of com- 
plexes in forskolin-treated cells suggests  that "stable" com- 
plex formation could be a misnomer in general. Instead, the 
accessibility of the IL-2 gene to sharply discontinuous regu- 
lation may result from rapid cycling of transcription factors 
between disassembled and reassembled states.  The rate of tran- 
scriptional initiation,  by this model,  would depend on the 
rate with which the most limiting component could be en- 
gaged. Such a model would explain how forskolin could first 
inhibit IL-2 expression to a modest degree, through reduc- 
tion in the TGGGC factor, and then more severely as NF-KB 
complexes also became rare. Further support for this interpre- 
tation is provided by the results of the experiments in which 
cells were stimulated normally, then subjected to a inhibitor 
chase. Forskolin and CsA work through completely different 
mechanisms, resulting in blocking the availability of different 
subsets of factors, yet both can shift the equilibrium to dis- 
sociation of active IL-2 transcription  complexes. 
This study adds a third set of transcription factors to those 
already known to be critical for physiological regulation of 
IL-2. As discussed in the introduction, inhibition of NF-AT 
and inhibition of AP-1 separately can block IL-2 expression. 
Neither of these factors is detectably inhibited by forskolin. 
Our results suggest a similar need for NF-KB, the TGGGC 
factors, and/or other factors that are sensitive to PKA activa- 
tion.  In vivo footprinting data are not yet available for any 
of the cases where AP-1  is  selectively inhibited.  However, 
generalizing from the effects of forskolin and the effects of 
CsA, we could predict that selective AP-1 inactivation would 
also destabilize the whole protein-DNA assembly at the IL-2 
enhancer. This would confirm a nonhierarchical requirement 
for the various  IL-2 regulatory factors.  Such  a  mechanism 
vividly  illustrates  how,  as  a  cell-specific  and  activation- 
dependent response,  IL-2 expression is rendered vulnerable 
to multiple  signaling  events. 
Figure  7.  Summary  of the availability  and in vivo  binding 
to the IL-2  enhancer of  different  transcription factors,  as mea- 
sured by gel mobility shift assays and in vivo footprinting 
in EL4 cells under different stimulation conditions. (Stim.) 
TPA+A23187;  (+CsA)  TPA+A23187+CsA;  (+FKL) 
TPA+A23187  + forskolin.  The pattern shown represents  results 
obtained when stimulation, in the presence  or absence  of the 
indicated agents, is carried out for at least 4 h. 
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